Pricing Log in Create free account

Vaxcyte, Inc. (PCVX) vs Spyre Therapeutics, Inc. (SYRE)

Vaxcyte, Inc. and Spyre Therapeutics, Inc. are both Biotechnology companies. Vaxcyte, Inc. and Spyre Therapeutics, Inc. are of similar size ($9.8B and $9.2B). Across the 11 metrics below, Spyre Therapeutics, Inc. leads on 9 and Vaxcyte, Inc. on 2.

Valuation

Metric PCVX SYRE Biotechnology median
P/E n/m n/m 10.60
P/S n/m 8,738.76 9.40
P/B 3.82 10.18 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales n/m 7,721.78 9.02
Earnings yield (12.64%) (2.95%) (32.88%)
Free cash flow yield (10.25%) (2.70%) (23.13%)

Profitability

Metric PCVX SYRE Biotechnology median
Gross margin 0.00% 100.00% 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (42.68%) (41.15%) (51.96%)
Return on assets (37.28%) (30.89%) (46.06%)
Return on invested capital (59.47%) 0.00% 0.00%

Growth

Metric PCVX SYRE Biotechnology median
Revenue growth (TTM) — (81.84%) 6.76%
EPS growth (last fiscal year) (48.16%) 55.24% 29.88%
Revenue growth, 5-year CAGR — (28.15%) 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric PCVX SYRE Biotechnology median
Debt to equity 0.04 0.00 0.00
Current ratio 4.56 27.40 4.97
Net debt to EBITDA 1.71 3.61 1.01

Dividend

Metric PCVX SYRE Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric PCVX SYRE Biotechnology median
Market cap 9.75b 9.17b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack